Wednesday, November 18, 2026

DuchemBio to Merge Subsidiary RadioD&S Labs, Hire Oh Seung-jun as CTO

Input
2026-07-23 08:58:50
Updated
2026-07-23 08:58:50
[Financial News] DuchemBio, a South Korean company specializing in radiopharmaceuticals, will absorb its subsidiary RadioD&S Labs to internalize research and development (R&D) capabilities and strengthen its contract development and manufacturing organization (CDMO) business. Dr. Oh Seung-jun, the founder of RadioD&S Labs, will join DuchemBio as Chief Technology Officer (CTO) alongside the merger.
DuchemBio said in a regulatory filing on the 23rd that it had decided to merge with its subsidiary RadioD&S Labs. Through the merger, the company will integrate the radiopharmaceutical candidates and nuclear medicine imaging technologies held by RadioD&S Labs with DuchemBio's production, quality control, and regulatory approval capabilities.
RadioD&S Labs is an R&D-focused company that studies radiopharmaceuticals and nuclear medicine imaging technologies. It was founded by Dr. Oh Seung-jun, a specialist in radiopharmaceuticals. After acquiring 100% of the company's shares in 2024 and bringing it in as a subsidiary, DuchemBio will now establish a system in which research, development, and commercialization are carried out within a single organization through this merger.
With the merger, DuchemBio plans to appoint Dr. Oh as CTO and move ahead in earnest with its radiopharmaceutical CDMO business. It also aims to accelerate the development of therapeutic radiopharmaceuticals (RPT), which the two companies are jointly pursuing, while expanding its own pipeline and strengthening its commercialization base.
CTO Oh is a radiopharmaceutical expert who led the domestic approval of the Parkinson's disease diagnostic radiopharmaceutical 18F-FP-CIT and the development of 18F-FES, a radiopharmaceutical for diagnosing metastatic breast cancer. He also developed an AI-based imaging prediction technology to shorten PET examination times and completed U.S. patent registration this year. DuchemBio is now working to commercialize the technology.
DuchemBio expects the merger to give it CDMO competitiveness across the full process, from candidate discovery to process development, production, and product approval. Radiopharmaceuticals are subject to strict manufacturing and quality control standards, so development and production experience is seen as a key factor in winning customers.
Kim Sang-woo, party leader of DuchemBio, said, "CTO Oh Seung-jun is an expert with broad experience in developing both diagnostic and therapeutic radiopharmaceuticals," and added, "We have secured CDMO capabilities that allow us to handle the entire process from candidate development to approval in a one-stop system."
CTO Oh Seung-jun said, "By combining RadioD&S Labs' R&D capabilities with DuchemBio's production and regulatory approval capabilities, I will build an integrated R&D system that covers the development, production, and approval of diagnostic and therapeutic radiopharmaceuticals," and added, "I will contribute to strengthening the competitiveness of our own RPT drug pipeline and CDMO business, helping the company grow into a firm recognized for its technological strength in the global radiopharmaceutical market."

[email protected] Jung Sang-hee Reporter